ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham.
Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) in addition to local and systemic inflammation. An abnormal microbiome induces further inflammation according to the company, creating a downward spiral. ResBiotic is developing first-in-class products that alleviate the neutrophilic inflammation associated with dysbiosis to improve respiratory health.
ResBiotic’s first product is a medical food that targets the gut-lung axis. The company says that the proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and development pipeline also includes pharmabiotics for multiple chronic lung diseases. These prescription probiotic treatments will be administered by nebulization, metered-dose inhaler, endotracheal tube or oral routes.
Founded in 2020, the company has raised Seed funding of $3M to help bring its first product to market in early 2022.
Subscribe for alerts on new companies featured on Startups.Bio
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …